Home » Newsletters » BioWorld Science

BioWorld Science

July 6, 2020

View Archived Issues

Tumor stroke-inducing nanoparticles effective in animals

Results of GRECCO-19 trial evaluating colchicine in hospitalized COVID-19 patients

Discovery of novel highly potent Mcl-1 inhibitor, APG-3526

Novel curcumin-peptide conjugate demonstrates efficacy in SORT1-positive cancer models

Terns patents THRbeta agonists

BlackThorn Therapeutics synthesizes vasopressin V1A antagonists

Takeda Pharmaceutical presents orexin OX2 receptor agonists

Roche describes new HBV antivirals

Ideaya Biosciences discovers MAT2A inhibitors

ZyCoV-D vaccine candidate for COVID-19 cleared to enter human trials in India

First patient dosed in phase II study of VB10.16 in combination with atezolizumab

Positive data presented from second pivotal phase III study of daridorexant

Potassium channel distancing fights stroke

Rapid platelet responses seen with rilzabrutinib in relapsed/refractory immune thrombocytopenia

Merck & Co. and Janssen to develop an AI-based diagnostic tool for neglected tropical diseases

EC grants conditional marketing authorization for Veklury as treatment of COVID-19

Phase II results presented for mitapivat in non-transfusion-dependent thalassemia

Hydroxychloroquine and lopinavir/ritonavir arms discontinued in Solidarity trial

Taisho's TP-0591816 is active against respiratory syncytial virus resistance mutants

Phase III data on Yselty in uterine fibroids support progression to regulatory filings

Reduction in enrollment in phase II trial of lanifibranor in patients with type 2 diabetes and NAFLD

Enrollment underway in phase I study of EPI-7386 for metastatic castration-resistant prostate cancer

First clinical data presented for BGB-A333 in patients with solid tumors

New phase II trial evaluates CBP-201 for moderate to severe atopic dermatitis

Regeneron's two-antibody cocktail REGN-COV2 for COVID-19 advances into late-stage trials

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 12, 2026
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...
Alzheimer’s, beyond the brain
BioWorld
Researchers at Daping Hospital in China have reported that liver-targeted delivery of the APOE3-Christchurch (APOE3Ch) variant, a rare protective form of...